Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

Trial investigates macrophage re-reprogramming immunotherapy bexmarilimab in combination with azacitidine to prevent relapse in MRD-positive AML after stem cell transplantation. TURKU, FI / ACCESS Newswire / February 19, 2026 / Faron Pharmaceuticals …